Physician profile
Daniel B Berry
NPI 1669431938
$18,812.02
in general payments reported to CMS, 2019-2025
61 companies · $3,138 in 2025
The $3,138 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,464 · 2020: $1,468 · 2021: $2,563 · 2022: $3,175 · 2023: $2,213 · 2024: $2,791 · 2025: $3,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,141 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,141.10 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,796.93 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,980.81 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,800.94 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Teva Pharmaceuticals USA, INC. | $1,432.23 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Amgen INC. | $983.95 | 2019-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $838.43 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $736.89 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Pfizer INC. | $713.04 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $599.53 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $586.66 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $557.76 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $497.83 | 2021-2025 | Rexulti, Nuedexta |
| Novartis Pharmaceuticals Corporation | $444.88 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $410.37 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $396.16 | 2019-2023 | Jardiance |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.